Lobular breast cancer: patterns of intraabdominal metastatic spread on imaging and prognostic significance
- 91 Downloads
To retrospectively review the frequency, patterns and intra-abdominal sites of metastatic invasive lobular breast cancer, and to correlate the findings with overall survival.
Materials and methods
From a pathology database search revealing 327 patients with metastatic lobular breast cancer at our institution from January 2004 through August 2014, imaging was available in 116 patients (age range, 31–87 years, mean age, 55). Simple descriptive statistics were performed to record and tabulate the abdominal metastatic spread. Prognostic significance of abdominal metastases and individual abdominal metastatic sites was studied using the Log-rank test and construction of Kaplan–Meier curves.
The most frequent sites of intra-abdominal metastatic invasive lobular breast cancer were peritoneum (55 patients, 47%), followed by liver (37 patients, 32%), bowel (34 patients, 29%), ovary (33 patients, 28%), retroperitoneum (16 patients, 14%), ureter (16 patients, 14%), and lymph nodes (15 patients, 13%). Bowel obstruction was noted in 15 patients (13%) and hydronephrosis in 25 patients (22%). The median abdominal metastasis-free survival was 76 months (interquartile range: 17–191). The overall survival (OS) was 86 months (interquartile range: 49–188). Patients with abdominal metastases had shorter OS. Patients with hepatic metastases had shorter overall survival than those patients without hepatic metastases (p = 0.02, Log-Rank test).
Invasive lobular breast cancer has a predilection for metastasizing to both typical (liver) and atypical intra-abdominal sites (peritoneum, GI tract, and adnexa). Presence of intra-abdominal disease and hepatic metastases in patients with ILC negatively affects overall survival.
KeywordsInvasive lobular Breast cancer Metastases CT
Compliance with ethical standards
Conflict of interest
Pamela J. DiPiro declares that she has no conflict of interest. Sree Harsha Tirumani declares that he has no conflict of interest. Gisele P Cruz declares that she has no conflict of interest. Nikhil H Ramaiya declares that he has no conflict of interest. Susan C Lester declares that she has no conflict of interest. Atul B. Shinagare is a consultant for Arog Pharmaceuticals and has received research funding from GTx, Inc.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
- 1.CDC-Breast Cancer Statistics [Internet] (2018) Available from: https://www.cdc.gov/cancer/breast/statistics/
- 4.Borst MJ, Ingold JA (1993) Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. Surgery 114(4):637–641 (discussion 641–642)Google Scholar
- 13.Shakoor MT, Ayub S, Mohindra R, Ayub Z, Ahad A (2014) Unique presentations of invasive lobular breast cancer: a case series. Int J Biomed Sci IJBS 10(4):287Google Scholar
- 14.Sobinsky JD, Willson TD, Podbielski FJ, Connolly MM (2013) Unusual metastatic patterns of invasive lobular carcinoma of the breast. Case Rep Oncol Med 2013:986517Google Scholar
- 19.O’Connell FP, Wang HH, Odze RD (2005) Utility of IHC in distinguishing primary adenocarcinomas from metastatic breast carcinomas in the GI tract. Arch Pathol Lab Med 129(3):338–347Google Scholar
- 20.Geller SA, Lin C (1975) Ureteral obstruction from metastatic breast carcinoma. Arch Pathol 99(9):476–478Google Scholar